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Background: The role of home parenteral nutrition (HPN) in incurable cachectic cancer patients unable to eat is
extremely controversial. The aim of this study is to analyse which factors can inﬂuence the outcome.
Patients and methods: We studied prospectively 414 incurable cachectic (sub)obstructed cancer patients receiving
HPN and analysed the association between patient or clinical characteristics and surviving status.
Results: Median weight loss, versus pre-disease and last 6-month period, was 24% and 16%, respectively. Median
body mass index was 19.5, median KPS was 60, median life expectancy was 3 months. Mean/median survival was
4.7/3.0 months; 50.0% and 22.9% of patients survived 3 and 6 months, respectively. At the multivariable analysis, the
variables signiﬁcantly associated with 3- and 6-month survival were Glasgow Prognostic Score (GPS) and KPS, and
GPS, KPS and tumour spread, respectively. By the aggregation of the signiﬁcant variables, it was possible to dissect
several classes of patients with different survival probabilities.
Conclusions: The outcome of cachectic incurable cancer patients on HPN is not homogeneous. It is possible to identify
groups of patients with a ≥6-month survival (possibly longer than that allowed in starvation). The indications for HPN can
be modulated on these clinical/biochemical indices.
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introduction
The indication for home parenteral nutrition (HPN) in incur-
able patients who are unable to eat, mainly for malignant
obstruction, is extremely controversial and its use in Europe is
considerably different from one country to another, accounting
for 60% of all patients’ population on HPN in the Netherlands
and Italy to only 5% in the UK, while the remaining European
countries are in between [1].
This is not unexpected because a variety of cultural factors,
traditions, religious beliefs, local preferences, as well as a multi-
tude of other social and economic factors inﬂuence decision
making in nutrition for both healthy and ill people [2].
Some authors, following a simple logic of cost/effectiveness
ratio, do not recommend HPN because, while most of patients
with benign intestinal failure can survive many years ‘thanks’ to
HPN, most of patients with malignant obstruction die within
weeks or months ‘despite’ HPN. On the contrary, others argue
that some of these cancer patients actually die ‘with’ the tumour
but not ‘because’ of the tumour, but because of starvation. In
fact, some selected studies of incurable cancer patients receiving
HPN because of malignant (sub)obstruction report a median
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survival of 5–6 months or more, which is longer than the usual
survival time after total macronutrient deprivation (∼2–2.5
months for healthy people) (references in [3]). These patients, if
not nutritionally supported, would obviously die due to under-
nutrition rather than to tumour progression.
Few studies (and none prospectively) have reported that
Karnofsky Performance Status (KPS), level of serum albumin
and of serum cholinesterase are prognostically signiﬁcant (refer-
ences in [3]); however, these scattered data proved unsuitable to
guide the clinician in the recommendation of HPN. As a conse-
quence, the European [4] and American [5] guidelines on HPN
are also quite vague on this issue.
Rather than assuming a dogmatic position when facing this
dilemma, we felt that a prospective investigation aimed to deﬁne
if some patient- or tumour- related characteristics are associated
with survival length, would be worthwhile.
patients andmethods
study design and patients
The idea of investigating which factors may be signiﬁcantly associated with
the survival of incurable cancer patients receiving HPN was originally con-
ceived within the Home Artiﬁcial Nutrition Working Group (HANWG) of
the European Society for Clinical Nutrition and Metabolism. A prospective
protocol was approved by the members of the HANWG and distributed to
Centres potentially involved in HPN programmes in cancer patients. On
each patient’s discharge, participating centres were asked to ﬁll up an ad hoc
form including the following data: demographic, nutritional [usual and
current body weight, body mass index (BMI)], clinical–oncological (life ex-
pectancy, KPS, site of primary, histopathology, tumour spread and vital
organ involvement, previous oncologic treatments), biochemical variables
[blood cell count, serum albumin, C-reactive protein (CRP)], indications for
HPN, start date, end date and method of HPN administration and manage-
ment and date of death. Furthermore, centres were required to provide add-
itional information concerning major complications, HPN withdrawal and
likely cause of death (HPN-related, organ failure or progressive wasting). For
all surviving patients, it was required a minimum period of observation of at
least 6 months. Body weight loss and the Glasgow Prognostic Score (GPS)
were then calculated.
Centres recommended HPN according to individual institutional policies
without any interference by HANWG responsible for the protocol, in com-
pliance with the purposes of an observational study.
The patient admission criteria were the following: adults/elderly patients
with no or negligible oral/enteral nutrition (usually because of intestinal
obstruction/sub-obstruction, diagnosed on clinical/radiological ground and
refractory to previous medical care), presence of an incurable malignancy,
without major organ failure or major involvement of a vital organ or severe
metabolic derangement. In addition, patients with ascites or pleural effusion
(which might be exacerbated by the ﬂuid infusion) and those with uncon-
trolled symptoms or those receiving HPN in the perspective to become can-
didate to a future oncologic treatment were excluded. It was required the
prescription of an i.v. nutritional daily regimen including at least 25 kcal and
1 g amino acid/kg bodyweight. Each centre was granted permission to take
part to the study from its own local Human Investigations Committee.
statistical analysis
Descriptive analyses were based on standard statistics such as relative fre-
quencies for categorical variables (gender, age class, tumour site, tumour
spread, main extent of disease, vital organ involvement, most recent therapy,
GPS) or with medians and ranges for continuous variables (age, relative
weight loss, BMI, CRP, serum albumin, KPS). Relative weight loss was com-
puted either with reference to the usual weight, or with respect to the weight
measured 6 months before HPN start; the latter value was also treated as
categorical towards a 10% classiﬁcation cut-off.
The study end point was overall survival (OS), calculated from the date of
HPN start to the date of death for any cause, with censoring at the date of
last follow-up assessment in alive subjects. The minimum follow-up duration
for the latter was 6 months. Survival data were summarized by computing
the OS curve with the Kaplan–Meier method. However, for the sake of sim-
plicity, statistical analyses were carried out considering survival status at 3 or
6 months as a dichotomous variable.
In order to investigate the association between distinct patient or clinical
characteristics and 3- or 6-month survival, Pearson’s χ2 tests were used for
univariable analyses, while logistic regression models were used for multi-
variable analyses.
Two-sided P values below the conventional 5% threshold were considered
statistically signiﬁcant. Statistical analyses were carried out with the SAS
package (Version 9.2, SAS Institute, Cary, NC) and R software (R
Foundation for Statistical Computing, Vienna, Austria).
results
study population
Thirteen centres from 10 different countries collected informa-
tion for 419 consecutive, incurable cancer patients receiving
HPN during a 6-year period (between November 2004 and
March 2011). Five patients were not considered for the following
reasons: HPN as a part of an already planned subsequent onco-
logic therapy (two cases); impossible diagnostic differentiation
between incurable disease and radiation enteropathy (one case);
missing follow-up information (two cases). Consequently, the
investigated sample included 414 patients.
Series characteristics are summarized in Table 1. Noteworthy,
patients were severely malnourished, as reﬂected by a median
weight loss, 24% of the usual weight and 16% of the weight mea-
sured 6 months before entering into the study and a median
BMI of 19.5. Median KPS was 60, median life expectancy was 3
months, more than half patients had a primary abdominal
gastrointestinal tumour, (sub)obstruction occurred as indication
for HPN in approximately two thirds of the cases.
Patients’ age was 65 years or older in 41% of the cases, and
92% of the patients were classiﬁed as stage IV according to the
SCRINIO classiﬁcation of cancer cachexia [6].
The i.v. nutritional support was continued till patient’s death
in the majority of cases, and withdrawn earlier in one third of
them (n = 139, 33.6%) for the following reasons: pre-agonic
status (n = 101, 24.4%), patient/relatives refusal (n = 29, 7.0%);
onset of HPN-catheter-related complications (n = 9, 2.2%). For
these 139 patients, median survival time after HPN discontinu-
ation was 2 months (range 1–126 months) overall. Median sur-
vival time was longer in the subsets of patients who discontinued
HPN because of patient/relatives refusal (5 months, range 1–61)
or HPN-catheter related complications (6 months, range 3–49).
survival analysis
At study conclusion, all patients except 12 (2.9%) were dead.
Median survival, 3.0 months (95% conﬁdence interval 2.7–3.3
months) in the overall series (Figure 1), showed little between-
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centre variability (from 1.3 to 4.5, with widely overlapping
conﬁdence limits, when estimable).
At 3 and 6 months after HPN start, 50.0% and 22.9% patients
were alive, respectively. The 3- and 6-month survival estimates
were 56.9% and 27.7%, respectively, for patients without meta-
static involvement of vital organs at the start of HPN, and 44.9%
and 16.4%, respectively, for those with vital organ involvement.
With reference to the 143 patients (approximately one-third
of the series) with the so-called refractory cachexia [7], 3- and
6-month survival dropped to 29.4% and 8.4%. These ﬁgures
were 31.7% and 12.2% for patients without vital organ involve-
ment, 27.1% and 5.9% for those with vital organ involvement.
Table 1. Main patient and disease characteristics
N %
Overall 414 –
Gender
Female 190 45.9
Male 224 54.1
Age, years
Up to 64 244 58.9
65 or higher 170 41.1
Median (range) 62 (16–90)
Relative weight loss, % (83 missing)
Median (range) 24 (−8a–56)
Relative weight loss in the last 6 months, % (84 missing)
Median (range) 16 (−44b–50)
BMI, kg/m2 (2 missing)
Overall: median (range) 19.5 (12.8–30.0)
Age <65 years: median (range) 19.5 (12.9–30.0)
Age ≥65 years: median (range) 19.6 (12.8–27.7)
Karnofsky Performance Status (26 missing)
Median (range) 60 (20–100)
Life expectancy, months (8 missing)
Median (range) 3 (0–24)
CRP, mg/l (43 missing)
Median (range) 8.0 (0.0–321.0)
Serum albumin, g/100 ml (19 missing)
Median (range) 3.2 (1.8–5.0)
Glasgow Prognostic Score
0 60 16.6
1 172 47.5
2 130 35.9
N.A. 2 –
Overall 414 –
Tumour site
Head and neck 50 12.1
Stomach 92 22.2
Small bowel–biliary 10 2.4
Colon–rectum 84 20.3
Ovary 51 12.3
Pancreas 46 11.1
Other 81 19.6
Histological type
Carcinoma 378 91.75
Sarcoma 13 3.16
Melanoma 6 1.46
Mesothelioma 4 0.97
Glioblastoma 3 0.73
Pseudomixoma 3 0.73
Lymphoma 2 0.49
Neuroendocrine 2 0.49
N.A. 2 –
Tumour spread
Locoregional 131 32.2
Metastatic 105 25.8
Both 171 42.0
N.A. 8 –
Main extent of disease
Extra-abdominal 60 16.1
Intra-abdominal 269 72.3
Continued
Table 1. Continued
N %
Both 43 11.6
N.A. 42 –
Vital organ involved
No 137 41.4
Yes 194 58.6
N.A. 83 –
Most recent therapy
Surgery 53 16.9
RT 24 7.6
CT 1st line 89 28.3
CT 2nd line 71 22.6
CT 3rd line 77 24.5
N.A. 100 –
BMI, body mass index; N.A., not available; CRP, C-reactive protein.
aOne patient showed increased weight, two stable weight.
bSix patients showed increased weight, two stable weight.
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Figure 1. Overall survival curve of the entire series.
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Cause of death, either overall or according to the presence/
absence of vital organ involvement at HPN start, is shown in
Table 2.
association between main factors
and surviving status
Number and percentage of surviving patients and P values at the
univariable analyses are reported in Table 3. Signiﬁcant results
were obtained for tumour spread, vital organ involvement, KPS
and GPS on both end points, and for relative weight loss on
6-month survival only. However, in the multivariable analyses
(Table 4), a signiﬁcant and independent prognostic effect was
conﬁrmed for KPS and GPS on 3- and 6-month survival, and for
tumour spread on 6-month survival. Survival probability ﬁgures
estimated for the combination of the above factors are shown in
Table 5. One may observe the substantial variability of survival
ﬁgures. In particular, 3-month survival ranged from a minimum
of 33% for patients with KPS≤ 50 and GPS = 2 to a maximum of
79% for patients with KPS > 50 and GPS = 0. As regards to
6-month survival, a minimum of 6% was estimated for patients
with KPS≤ 50, GPS = 2 and extensive tumour spread, while a
maximum of 61% was estimated for patients with KPS > 50,
GPS = 0 and locoregional tumour spread.
discussion
This study involved 414 cachectic patients with an incurable
malignancy receiving HPN, mainly for intestinal (sub)obstruc-
tion and without a concurrent oncologic therapy. Median rela-
tive weight loss was 24% and 92% of them had a weight loss
≥10% which means that almost all could be deﬁned as cachectic
according to two validated cancer cachexia classiﬁcations
published in literature [6, 8].
We observed a mean/median survival of 4.7/3.0 months, a
ﬁnding quite similar (or a bit lower) to that of many retrospect-
ive and prospective series and in agreement with the common
expectation in advanced cancer patients belonging to an area of
simple palliation (references in [3]).
The statistically signiﬁcant prognostic variables were KPS,
tumour spread (categorized as local-locoregional, metastatic or
both) and GPS. Except for KPS, which was already reported in
literature, tumour spread and GPS were never investigated
before. All these indexes are simple, commonly reported in the
oncologic charts, objective and can be easily quantiﬁed.
In absence of a proper control group, we cannot deﬁnitely
assess which was the clinical impact of HPN. However, from a
careful scrutiny of the literature (references in [3]), we found
that the survival of patients with malignant obstruction usually
does not exceed 2 months if no PN support is supplied during
the hospital stay and is further reduced to <2–3 weeks if patients
are followed at home.
In contrast, our data showed that about 50% of the patients
on HPN survived longer than what is usually observed in histor-
ical controls, and approximately one-quarter survived 6 months
or longer—median survival beyond 6 months being 4.1 months.
Hence, it might be that these patients beneﬁtted from HPN in
terms of longer survival. We are aware that no hard data are
supporting this statement; however, parenteral nutrition of
(hypo)aphagic patients is somewhat viewed as a life-saving pro-
cedure because some incurable cancer patients can survive
several months [9] but the onset of aphagia drastically reduces
the survival time to few weeks. In addition, a RCT to deﬁnitely
set the issue would be considered unethical by many nutrition-
ists and, on the contrary, an over-treatment by some clinicians
who fear PN might only prolong and worsen symptoms of the
patients.
With reference to 3-month survival, we observe that, combin-
ing information on the GPS and the KPS, distinct patients
populations at higher or lower chance of survival may be discri-
minated (Table 5). Similarly, the combinations of the KPS, the
GPS and the pattern of tumour spread leads to 18 distinct
patient groups, whose survival at 6 months ranges from only 5%
to a clinically relevant 43.7% (Table 5).
In summary, depending on the aggregation of different prog-
nostic variables, it turns out that apparently homogeneous in-
curable weight-losing patients may in fact be prognostically
stratiﬁed. This could help clinicians to determine HPN indica-
tion in the individual patient.
Another pivotal component of patient outcome is the quality
of life. A survey [10] on the relevance of quality of life for
patients with advanced cancer showed that only 22% of them
would choose palliative chemotherapy, in preference to support-
ive care alone, to beneﬁt from the associated 3-month additional
survival advantage, in contrast, 68% would choose chemother-
apy if it substantially reduced adverse symptoms without
prolonging life. Since an ad hoc study [11] has shown that
quality of life starts to decline in the last 2–3 months of life of
these patients on HPN, this also would argue against recom-
mending HPN in patients with a prognosis of ≤3 months.
Table 2. Cause of death distribution in the whole series and
according to vital organs involvementa
N %
Whole series 402
HPN/CVC complications 5 1.2
Vital organ failure 185 46.0
Progressive wasting 136 33.8
Unknown 76 18.9
Vital organs not involved 133
HPN/CVC complications 2 1.5
Vital organ failure 31 23.3
Progressive wasting 88 66.2
Unknown 12 9.0
Vital organs involved 190
HPN/CVC complications 3 1.6
Vital organ failure 131 68.9
Progressive wasting 24 12.6
Unknown 32 16.8
CVC, central venous catheter.
aThe number of deaths in patients with or without organs involved
does not add up to the total number of deaths because of the
exclusion of 79 dead patients with missing information on organ
involvement.
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It is noteworthy that about one-third of the patients of this
series would have been considered as belonging to the ‘refrac-
tory cachexia’ stage by Fearon et al. [7], yet the mean/median
survival of this group was 2.8/2.1 months (3.0/2.6 months in
patients without metastatic involvement of vital organs) that
means that a small percentage of them could have beneﬁtted
from HPN. This argues against the recommendations of these
authors who would deny HPN to all these patients and calls for
the need of revising current cancer cachexia classiﬁcations.
This study has some limitations: since patients died at
home, we cannot be sure about the causes of death even if
the protocol speciﬁed the classiﬁcation criteria. Moreover,
we lack enough information about the possible weaning
from HPN in the last days before death and about the exact
composition of the nutritional bags and whether these com-
plied with ESPEN recommendations [4] which suggest a
relatively high fat to carbohydrate ratio and a high protein
load.
In conclusion, our data show that there is a substantial vari-
ability in the survival of incurable cachectic patients on HPN,
and that such variability is partly explained on the basis of few
and simple prognostic factors which may be taken into account
Table 3. Number (N) and percentage (%) of surviving patients at 3 and 6 months
3 months 6 months
Category (reference) N % P N % P
Gender
Female 92 48.4 0.554 44 23.2 0.925
Male 115 51.3 51 22.8
Age, years
Up to 64 122 50.0 1.000 57 23.4 0.810
65 or higher 85 50.0 38 22.4
Relative weight loss (83 missing)
<20 54 46.2 0.469 35 29.9 0.013
20–30 58 50.4 16 13.9
≥30 54 54.6 22 22.2
Relative weight loss in the last 6 months (84 missing)
<13 53 50.0 0.920 29 27.4 0.235
13–20 55 49.1 20 17.9
≥20 58 51.8 24 21.4
BMI (2 missing)
≤18.5 79 51.3 0.741 29 18.8 0.116
>18.5 128 49.6 66 25.6
Karnofsky Performance Status (26 missing)
Up to 50 72 37.5 <0.001 19 9.9 <0.001
>50 118 60.2 66 33.7
Glasgow Prognostic Score (52 missing)
0 43 71.7 0.001 23 38.3 0.001
1 83 48.3 38 22.1
2 57 43.8 19 14.6
Tumour site 0.285 0.448
Head and neck 28 56.0 13 26.0
Stomach 53 57.6 17 18.5
Small bowel–biliary 5 50.0 2 20.0
Colon–rectum 44 52.4 26 31.0
Ovary 25 49.0 13 25.5
Pancreas 20 43.5 9 19.6
Other 32 39.5 15 18.5
Tumour spread (7 missing) 0.008 <0.001
Locoregional 80 61.1 47 35.9
Metastatic 51 48.6 19 18.1
Both 74 43.3 27 15.8
Main extent of disease (42 missing) 0.190 0.448
Extra-abdominal 31 51.7 11 18.3
Intra-abdominal 140 52.0 63 23.4
Both 16 37.2 7 16.3
Vital organ involvement (83 missing) 0.030 0.014
No 78 56.9 38 27.7
Yes 87 44.8 32 16.5
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for assessing HPN indication. While in patients with the best
(or the worst) prognostic scores, it is likely easy to reach an
agreement on the indication to start (or not to start) a pro-
gramme of HPN, the recommendation is more controversial in
intermediate conditions.
In such cases, we state as important that health professionals,
recognizing that feeding is a fundamental element in human
relationships and culture, approach these decisions with a
special sensitivity for concerns about starvation and abandon-
ment and families’ desire to provide love and care.
Table 4. Results from the logistic multiple regression model used to investigate the factors associated with 3- and 6-month survival: odds ratio (OR),
95% conﬁdence interval (CI) and P value
3 months 6 months
Category (reference) OR (95% CI) P OR (95% CI) P
Age, years
IQ range: 54–69 1.12 (0.85–0.47) 0.430 1.00 (0.71–1.39) 0.978
Gender
Female (male) 0.90 (0.56–1.43) 0.652 0.86 (0.48–1.52) 0.602
Relative weight loss 10%
Yes (no) 1.04 (0.57–1.88) 0.724 0.94 (0.46–1.92) 0.899
N.A. (no) 0.76 (0.33–1.78) 0.79 (0.29–2.16)
Tumour site
Biliary–pancreas (upper GI) 0.52 (0.26–1.06) 0.180 0.78 (0.32–1.94) 0.113
Colon–rectum (upper GI) 0.91 (0.50–1.68) 2.24 (1.06–4.70)
Ovary (upper GI) 0.86 (0.39–1.90) 1.52 (0.57–4.04)
Other (upper GI) 0.53 (0.28–0.99) 0.85 (0.39–1.89)
Tumour spread
Metastatic (locoregional) 0.55 (0.29–1.03) 0.113 0.39 (0.19–0.83) 0.018
Locoreg. and Metast. (locoregional) 0.57 (0.32–1.03) 0.39 (0.19–0.81)
Main extent of disease
Extra-abdominal (intra-abdominal) 0.76 (0.36–1.58) 0.637 0.54 (0.22–1.37) 0.294
Extra- and intra-abd. (intra-abdominal) 0.62 (0.29–1.34) 0.94 (0.34–2.60)
N.A. (intra-abdominal) 0.88 (0.35–2.19) 1.59 (0.56–4.53)
Vital organ involvement
Yes (no) 0.91 (0.52–1.59) 0.272 0.84 (0.41–1.71) 0.857
N.A. (no) 0.58 (0.30–1.13) 0.85 (0.40–1.78)
Glasgow Prognostic Score
1 (0) 0.30 (0.15–0.61) 0.006 0.39 (0.18–0.84) 0.016
2 (0) 0.29 (0.14–0.61) 0.25 (0.11–0.61)
N.A. (0) 0.32 (0.13–0.75) 0.60 (0.23–1.60)
Karnofsky Performance Status
Up to 50 (>50) 0.38 (0.25–0.60) <0.001 0.24 (0.13–0.43) <0.001
IQ, interquartile; N.A., not available; GI, gastrointestinal.
Table 5. Estimated 3-month and 6-month survival probability
Karnofsky Performance Status Glasgow Prognostic Score 3-month probability 6-month probability
Tumour spread
Locoregional Metastatic Both
Up to 50 0 0.599 0.274 0.155 0.139
1 0.356 0.156 0.083 0.074
2 0.333 0.109 0.056 0.050
>50 0 0.790 0.613 0.435 0.404
1 0.583 0.437 0.274 0.250
2 0.558 0.338 0.199 0.180
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Exercise program improves therapy-related side-effects
and quality of life in lymphoma patients undergoing
therapy
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Background: Lymphoma patients undergoing therapy must cope with the side-effects of the disease itself, therapy and
associated immobility. Peripheral neuropathy (PNP), loss of balance control and weakness not only diminishes patients’
quality of life (QOL), it can also affect planning and the dosage of therapy. Exercise may enable patients to reverse these
declines, improving their performance level and QOL.
Patients and methods: We carried out a randomized, controlled trial, assigning 61 lymphoma patients either to a
control group (CG; N = 31) or to a 36-week intervention (IG; N = 30), consisting of sensorimotor-, endurance- and
strength training twice a week. Primary end point was QOL; secondary end points included movement coordination,
endurance, strength and therapy-induced side-effects.
Results: Intergroup comparison revealed improved QOL- (ΔT1–T0; P = 0.03) and PNP-related deep sensitivity in the IG:
87.5% were able to reduce the symptom, compared with 0% in the CG (P < 0.001). Signiﬁcant differences in the change of
balance control could be found between the groups, with the IG improving while the CG steadily declined (monopedal static
ΔT3–T0; P = 0.03; dynamic ΔT3–T0; P = 0.007; perturbed mono-ΔT3–T0; P = 0.009 and bipedal ΔT3–T0; P = 0.006), failed
attempts (monopedal static ΔT3–T0; P = 0.02, dynamic ΔT3–T0; P < 0.001and perturbed ΔT3–T0; P = 0.006) and improved
time to regain balance (ΔT3–T0; P = 0.04). Moreover, the change in the aerobic performance level (ΔT3–T0; P = 0.05) and add-
itional amount of exercise carried out per week [metabolic equivalent (MET); P = 0.02] differed signiﬁcantly across groups.
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Department of Hematology and Oncology, Hugstetter Str. 55, D-79106 Freiburg,
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